Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seres Therapeutics, Inc. on March 16, 2026. The filing announces the scheduling of the Company's 2026 Annual Meeting of Stockholders and provides updated deadlines for stockholder proposals.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance.
Material Changes
There are no material financial changes reported in this filing. The primary event is the administrative scheduling of the 2026 Annual Meeting for June 9, 2026.
Guidance, Outlook, and Corporate Events
- Annual Meeting Date: June 9, 2026.
- Record Date: April 13, 2026 (holders of record as of this date are entitled to vote).
- Meeting Details: Specific time and location will be disclosed in the definitive proxy statement.
- Stockholder Proposal Deadline: Due to the meeting being held more than 30 days after the anniversary of the 2025 meeting, the deadline for Rule 14a-8 proposals is March 26, 2026.
Key Facts for Investor Verification
- Verify the record date of April 13, 2026, to determine voting eligibility.
- Monitor the upcoming definitive proxy statement for the specific time and location of the June 9, 2026, meeting.
- Note the March 26, 2026, deadline for submitting qualified stockholder proposals.